Rueda-Fernandez, ManuelMelguizo-Rodriguez, LuciaCostela-Ruiz, Victor JGonzalez-Acedo, AnabelRamos-Torrecillas, JavierIllescas-Montes, Rebeca2023-05-032023-05-032022-08-19Rueda-Fernández M, Melguizo-Rodríguez L, Costela-Ruiz VJ, González-Acedo A, Ramos-Torrecillas J, Illescas-Montes R. The current status of COVID-19 vaccines. A scoping review. Drug Discov Today. 2022 Nov;27(11):103336.http://hdl.handle.net/10668/22156Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new disease that has led to a worldwide pandemic, resulting in millions of deaths and a high economic burden. Here, we analyze the current status of preventive vaccines authorized by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). Published clinical trials have shown the effectiveness of mRNA (BNT162b2 and Spikevax), adenovirus vector-based (Ad26.COV2.S and ChAdOx1 nCoV-19), and recombinant protein S (NVX-CoV2373) vaccines to be between 52.9% and 100%. The most-frequent adverse effects include local pain, fatigue, headache, or chills. Serious events are associated with Ad26.COV2.S and ChAdOx1 nCoV-19 vaccines.enHumansNVX-CoV2373 adjuvated lipid nanoparticleChAdOx1 nCoV-19SARS-CoV-2BNT162 VaccineAd26COVS12019-nCoV Vaccine mRNA-1273Financial StressPandemicsUnited States Food and Drug AdministrationVaccines, SyntheticIatrogenic DiseaseHeadachePainAdenoviridaeresearch article35995361Restricted AccessAdenoviridaeCefaleaEnfermedad iatrogénicaEstrés financieroPanPandemiasAdministrationVacuna BNT162Vacuna nCoV-2019 mRNA-1273Vacunas sintéticas10.1016/j.drudis.2022.08.0041878-5832PMC9389839https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389839https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389839/pdf